Peru: INS Issues Guidelines for Clinical Trials during COVID-19 Emergency
July 7, 2020
On June 26, 2020, Peru’s National Institute of Health (Instituto Nacional de Salud (INS)) issued Guidelines for the Conduct of Clinical Trials during the Health Emergency Due to COVID-19. The guidelines aim to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practices, and minimizing risks to trial integrity. (Google translation of guidelines)
On June 30, 2020, the INS issued Communique 005-2020-OGITT/INS, which provides instructions for filing information for COVID-19 related studies and non-COVID-19 studies. (Google translation of Communique 005-2020-OGITT/INS)
For details on all of Peru' clinical research regulatory requirements, view the Peru country profile.